Advanced CQA Characterization of GLP-1 Agonists with SEC-MALS

Presented by: Udayabagya (Bud) Halim (Waters | Wyatt Technology)
Presented Live: October 15, 2025

GLP-1 receptor agonists (GLP-1RAs), which are now central to diabetes and weight management therapy, require precise and dependable analytical procedures throughout development, production, and quality control.

This webinar explores how light-scattering techniques, such as dynamic light scattering (DLS) and multi-angle light scattering (MALS), enable comprehensive assessment of critical quality attributes (CQAs).

The webinar also examines how MALS, combined with size-exclusion chromatography (SEC-MALS) under native and denaturing conditions, provides accurate, quantitative data on molar mass, size, aggregation, and oligomeric state, as well as their impact on colloidal stability.

Case studies will demonstrate the characterization of GLP-1 analogs such as liraglutide, semaglutide, and related peptides, with a focus on applications such as aggregation screening, impurity profiling, and stability analysis.

The session will cover how the latest Empower Chromatography Data System includes modern detectors for orthogonal characterization in QC procedures, ensuring secure and compliant data handling to enhance product integrity and regulatory compliance.

Other Webinars from Waters | Wyatt Technology

Tell Us What You Think

Do you have a review, update or anything you would like to add to this content?

Leave your feedback
Your comment type
Submit

Materials Webinars by Subject Matter

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.